Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Study: Older breast cancer patients have better survival rates than what is predicted by ePrognosis tool

Older women with early-stage, invasive breast cancer had better survival rates than what was estimated by a popular online tool for predicting survival, according to researchers at the Duke Cancer Institute.

9 Dec 2015

Aspirin does not improve survival among breast cancer patients with aggressive disease

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise.

9 Dec 2015

Providing cancer patients with counseling before and after testing for genetic mutations decreases anxiety

Many BRCA 1/2-negative patients choose to proceed with comprehensive testing for genetic mutations that increase cancer risk, and when presented with counseling before and after testing, most make informed decisions and experience decreased levels of anxiety, according to new research from the Perelman School of Medicine at the University of Pennsylvania and the Basser Center for BRCA in Penn's Abramson Cancer Center.

9 Dec 2015

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

9 Dec 2015

Yale study explores link between body fat, weight loss and telomere length in breast cancer survivors

It is well documented that a healthy diet and exercise are key in cancer prevention and management, but the exact mechanism hasn't been clear. Now, Yale Cancer Center researchers have found an explanation in the tiny protective ends of chromosomes called telomeres. The findings will be presented Dec. 11 at the 2015 San Antonio Breast Cancer Symposium.

9 Dec 2015

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Rising Tide Foundation for Clinical Cancer Research, an international private foundation based in Switzerland, has awarded a US $800,000 grant to be released over two years for the ASCOLT study conducted by Dr John Chia, Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore.

9 Dec 2015

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.

9 Dec 2015

Roche announces regulatory clearance to finalize acquisition of Kapa Biosystems

Roche today announced regulatory clearance to finalize acquisition of Kapa Biosystems, Inc., a privately-held company headquartered in Wilmington, Massachusetts, US.

8 Dec 2015

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

A new collaborative program between scientists at SRI Biosciences, a division of SRI International, and physician-researchers from Stanford Cancer Institute will pursue development of novel compounds to treat multiple forms of cancer and other conditions.

8 Dec 2015

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease in the years that followed than those who didn't undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown.

8 Dec 2015

Web-based survey system for symptom collection benefits cancer patients

Systematic collection of cancer patients' symptoms using computer surveys was linked to less frequent emergency room admissions, longer average chemotherapy adherence, greater quality of life improvements, and improved survival, according to a new randomized, controlled trial spearheaded by a UNC Lineberger Comprehensive Cancer Center researcher.

8 Dec 2015

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

The new Loyola Center for Cancer Care & Research at Palos Community Hospital is offering cancer patients academic level care close to home.

8 Dec 2015

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015

Lancet study compares prices of new cancer drugs in high-income countries

The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found.

8 Dec 2015

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

8 Dec 2015

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.

7 Dec 2015

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research.

7 Dec 2015

Oncology News and Research

Further Reading

Study: Older breast cancer patients have better survival rates than what is predicted by ePrognosis tool

Aspirin does not improve survival among breast cancer patients with aggressive disease

Providing cancer patients with counseling before and after testing for genetic mutations decreases anxiety

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Yale study explores link between body fat, weight loss and telomere length in breast cancer survivors

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Roche announces regulatory clearance to finalize acquisition of Kapa Biosystems

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Web-based survey system for symptom collection benefits cancer patients

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Lancet study compares prices of new cancer drugs in high-income countries

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News